Valneva SE

Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

31 May 2024 11:35:00 By Nasdaq GlobeNewswire

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

21 May 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine

13 May 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

07 May 2024 01:00:00 By Nasdaq GlobeNewswire

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

06 May 2024 01:30:00 By Nasdaq GlobeNewswire

Declaration of voting rights - Valneva SE, March 2024

04 Apr 2024 12:00:00 By Nasdaq GlobeNewswire

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

26 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

25 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

21 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

20 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

18 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - February 29, 2024

06 Mar 2024 02:30:00 By Nasdaq GlobeNewswire

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

04 Mar 2024 01:00:00 By Nasdaq GlobeNewswire

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

29 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

15 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

VALNEVA: Declaration of shares and voting rights - January 31, 2024

07 Feb 2024 02:30:00 By Nasdaq GlobeNewswire

Valneva Announces Sale of Priority Review Voucher for $103 Million

05 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine

10 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: December 31, 2023

05 Jan 2024 02:30:00 By Nasdaq GlobeNewswire

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

04 Jan 2024 11:45:00 By Nasdaq GlobeNewswire